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Introduction
Acute cystitis is a condition for which the 
community pharmacist is likely to come 
across on a regular basis. This condition 
is normally characterised by dysuria, 
urgency and/or frequency. However such 
classical symptoms may not be apparent in 
the elderly who may instead present with 
confusion or incontinence. The presence of 
symptoms such as fever, chills or back pain 
are indicative of bacteraemia as well as 
kidney involvement. Referral is also always 
indicated in the latter cases, as is also for 
all cases of lower urinary tract infections 
in men, children and pregnant women. The 
community pharmacist should also be aware 
that there are other causes for dysuria, such 
as sexually transmitted diseases.1 Suspicion 
of such infections should always be referred 
for appropriate treatment.
Bacteriuria does not always present 
with symptoms. Asymptomatic bacteriuria 
is a common occurrence in the elderly as 
well as catheterised patients and does not 
merit treatment. Treatment of asymptomatic 
conditions in the elderly does not decrease 
the frequency of symptomatic infection but 
increases the risks of adverse drug reaction 
and promotes urinary tract infection with 
resistant organisms.2 In cases of long-term 
indwelling catheters there is conﬂicting 
evidence on whether use of antibiotics in 
asymptomatic patients reduces the frequency 
of symptomatic episodes but repeated use of 
antibiotics increases the risk of colonisation 
by resistant bacteria.2
OTC preparations for the treatment and 
prophylaxis of cystitis
Women presenting with symptoms of cystitis 
and who do not need to be referred should 
be advised to maintain adequate hydration. 
They can also be offered alkalinising 
agents for a couple of days, although the 
evidence base for this recommendation 
is limited. The use of alkalinising agents 
is not recommended in individuals with 
hypertension or heart failure as these 
preparations contain a high sodium or 
potassium content. Caution should be 
exercised when recommending potassium 
alkalinising preparations to patients on 
medication that predispose to hyperkalaemia 
eg ACE inhibitors and potassium sparing 
diuretics. Alkalinising agents should not be 
used in patients prescribed nitrofurantoin, 
as this drug requires an acidic urine pH to be 
effective.2
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Abstract
The antibiotic arsenal for treatment of lower urinary tract infection 
is becoming increasingly limited. Co-trimoxazole has been lost in 
the empirical treatment of urinary tract infection. Other agents 
particularly ﬂuoroquinolones are becoming ineffective. Locally, the 
empirical treatment of such infection focuses on two antibiotics 
– nitrofurantoin and co-amoxiclav. Carbapenems are increasingly 
being prescribed due to the emergence of ESBL (extended spectrum 
beta lactamase) positive pathogens.
Educational aims
s  To provide an overview of the OTC preparations available for the prophylaxis and 
treatment of acute uncomplicated cystitis
s  To highlight the reasons as to why nitrofurantoin and co-amoxiclav are the 
antimicrobials of choice in the empirical treatment of lower urinary tract infections
s  To illustrate the limitations of  nitrofurantoin treatment
s  To demonstrate why  ﬂuoroquinolones are not the ideal choice in the treatment of 
lower urinary tract infections
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Other OTC preparations that are 
commonly associated with cystitis are 
cranberry products. Evidence to support 
the use of these products for treatment of 
cystitis is lacking. The recommendation 
of such products should be restricted 
to the prevention of such infections in 
premenopausal women with a history of 
recurrent infections.2 Evidence is also lacking 
for the effectiveness of cranberry products 
for their prophylactic effect in the elderly 
and catheterised patients. The optimal 
dose has not been established but giving a 
minimum of 36 mg/day proanthocyanindin 
A (the active compound), is favoured.3  
It might be appropriate to recommend 
cranberry capsules as an alternative to 
the juice as a solid dosage form may be 
more convenient to the patient. The use 
of cranberry products is not generally 
recommended in patients on warfarin as 
interactions resulting in an increase the INR 
can occur.4
Cystitis originates primarily from 
pathogens in the bowel ﬂora. By far the 
most commonly implicated organism is 
Escherichia coli. Traditionally co-trimoxazole 
was prescribed for cystitis, however, over the 
past decades local resistance has developed 
to the degree that this antibiotic is no 
longer indicated in the empirical treatment 
of urinary tract infection. From local clinical 
practice this antibiotic retains its high 
efﬁcacy against MRSA. 
Empirical treatment in the community
Current local community guidelines indicate 
nitrofurantoin and co-amoxiclav as the 
drugs of choice.5 The exclusive indication 
of nitrofurantoin is cystitis. This drug 
lacks tissue penetration, only reaching 
therapeutic concentrations within urine. 
For this indication nitrofurantoin remains 
the most efﬁcacious oral agents with little 
acquired resistance over the 60 year period 
in clinical use. The bactericidal potency 
of nitrofurantoin is affected by pH, its 
potency reducing rapidly as urine becomes 
more alkaline. For this reason nitrofurantoin 
should not be prescribed for infections 
characterised with a urine pH greater than 
7. A high urinary pH may also be indicative 
of a pathogen that produces urease enzymes, 
such a Proteus or Serratia which are 
intrinsically resistant to nitrofurantoin.6
Nitrofurantoin has various mechanism of 
action, being bactericidal at concentration 
normally reached with therapeutic doses. 
Its spectrum of activity covers both 
gram positive as well as gram negative 
organisms including multidrug resistant 
strains such as MRSA, vancomycin-
resistant enterococci and the extended 
beta lactamase enterobacteriaceae (ESBL 
positive organisms). One drawback of this 
drug is that it is not licensed for use in 
patients with renal impairment deﬁned by an 
estimated glomerular ﬁltration rate (eGFR) of 
less than 60 ml/min. This makes the drug of 
limited use in the elderly.  However literature 
has shown that nitrofurantoin still remains 
effective in renal impairment and can be 
used with caution in patients with mild renal 
impairment.7,8,9 In such cases the drug is 
being prescribed off label.
Nitrofurantoin is prescribed on a 6 
hourly basis and should be taken with 
food primarily to improve absorption 
but also to limit GI side effects such as 
nausea (a side-effect which is less frequent 
with the macrocrystalline formulation). 
In premenopausal woman acute cystitis 
usually responds to 3 days treatment. In 
postmenopausal women or women having 
well-controlled diabetes without urological 
sequelae may be managed in the same way 
as for acute uncomplicated cystitis. But a 
7-day course is generally recommended since 
cure rates with short-course therapy are not 
as high.10
Co-amoxiclav is now the alternative to 
nitrofurantoin for the empirical treatment 
of cystitis. The higher dose formulations of 
co-amoxiclav have often been prescribed on 
a bd basis however the tds regimen is now 
generally recommended except for speciﬁc  
hepatic and renal considerations.11 For 
cystitis the recommended dose being 625mg 
every 8 hours. Previous to co-amoxiclav, 
cefuroxime was widely recommended, having 
a narrower spectrum than co-amoxiclav but 
still retaining activity against uropathogens.   
However the extensive overuse of 
cephalosporins has led certain gram negative 
pathogens to develop resistance by enzyme 
activity - ESBL, enzymes that destroy the 
beta-lactam ring. For this reason the use 
of cefuroxime within hospitals has been 
restricted.12
 
Restricting the use of ﬂuoroquinolones
The prescription of ﬂuoroquinolones for 
cystitis should be guided by laboratory 
results. Resistance to these antibiotics is 
at a signiﬁcant level.13 Limiting the use 
of ﬂuoroquinolones for when no suitable 
alternative is available is a strategy that 
will help mitigate increasing resistance 
to this class of antibiotics, not only to 
uropathogens but also to other pathogens 
including MRSA.14 When ﬂuoroquinolones 
are indicated ciproﬂoxacin is the favoured 
antibiotic for urinary tract infections, it has 
good pharmacokinetic properties, the oral 
formulation being well absorbed as well as 
being well concentrated within urine. A low 
dose (250mg bd) will sufﬁce. Furthermore 
ciproﬂoxacin is the gold standard in 
the treatment of infections caused by P 
aeruginosa. In such cases however a higher 
doses (500mg bd) should be considered 
as the minimum inhibitory concentration 
for P aeruginosa is higher than for 
other organisms. A good ﬂuid intake is 
recommended with the higher doses of 
ciproﬂoxacin as cases of crystaluria have 
been reported especially in alkaline urine. 
Since ciproﬂoxacin absorption is inhibited 
by multivalent metal ions, pharmacists 
should advice patients not to take this 
antibiotic with milk or milk products. 
Patients on calcium supplementation or 
multivitamin preparation should also be 
adviced to take their regular medication 
4 hours away from their antibiotic. 
Pharmacists should also be aware that 
ﬂuoroquinolones may lower the seizure 
threshold and may trigger seizures thus 
should be used with extreme caution in 
patients predisposed to seizures.15
Recurrent infections
Individuals with recurrent urinary tract 
infections (deﬁned as three episodes over 
the past year or two in the past six months) 
may be considered for a trial of antimicrobial 
prophylaxis for up to 6 months if symptoms 
are debilitating.2,16 Prophylactic antibiotics 
should be given at night when urine ﬂow 
is low. Longer term use is however not 
recommended as this promotes emergence 
of resistance. Antibiotic prophylaxis is 
generally not recommended in catheterised 
patients. However they may be considered 
if the frequency and intensity of symptoms 
impinge on the well-being of the individual.2
Empirical treatment in hospitals
Antibiotic choice for the empiric treatment 
of lower urinary tract infections in hospital 
is similar to community guidelines but in 
an era of increasing antibiotic resistance, 
routine urine sampling is recommended in 
symptomatic patients in order to determine 
the sensitivity of the pathogen.17 Urinary 
tract infection is the most common 
nosocomial infection and hospitalisation 
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should be considered a risk for infection with 
ESBL-producing pathogens. An increasing 
proportion of patients would have acquired 
such organisms before hospital admission, 
reﬂecting the regrettable over-prescribing 
of antibiotics in the community. Treatment 
with co-amoxiclav in such cases is likely 
to fail and these pathogens could also 
have acquired resistant to quinolones and 
aminoglycosides. Carbapenems are increasing 
becoming the only practical alternative 
treatment available locally. Ertapenem has 
an advantage over other carbapenems in 
that it is given on a once daily basis; it 
also has a narrower spectrum than other 
carbapenems, it does not cover Pseudomonas 
and Acinetobacter species. In Europe it is 
used off-licence for urinary tract infection, 
however it is registered for this indication 
in the US.18,19 Carbapenems are not available 
as oral formulations. Patients requiring such 
antimicrobials have to undergo IV therapy, 
an invasive procedure which in its own 
right predisposes to a hospital acquired 
infection.20 Some strains of Gram-negative 
organisms have also developed  resistance to 
carbapenems thus limiting further the choice 
of antibiotics. 
A risk for urinary tract infections – 
catheterisation
Urinary catheterisation is a common 
procedure in hospital and long-term care 
facilities. This procedure predisposes the 
individual to infection.20 Risk reduction 
should be considered - the need and duration 
for catheterisation should be carefully 
assessed. Alternatives such as suprapubic or 
condom catheters should be considered as 
these carry a lower incidence of urinary tract 
infections. The technique of intermittent 
catheterisation is also encouraged especially 
among spinal cord injury patients. Treatment 
of catheter associated urinary tract 
infections without kidney involvement is 
the same as for patients without catheter.17 
Treatment is only indicated in symptomatic 
patients, who would also merit a catheter 
change since bioﬁlms tend to develop rapidly 
along both the inner and outer surface of the 
catheter lumen creating a barrier to effective 
penetration by antibiotics and predisposing 
to resistance. Bioﬁlms are usually initially 
caused by single species but rapidly become 
polymicrobic.21  As a general guideline 
seven days of antimicrobial treatment for 
patients with catheter associated-UTI who 
have prompt resolution of symptoms is 
recommended, the duration is prolonged 
to 10–14 days for those with a delayed 
response.22
Pivmecillinam and Fosfomycin
Two other antibiotics indicated for urinary 
tract infection are available but have not 
been discussed above since, as yet, they 
are not registered locally.  Both of these 
antibiotics have been listed as ﬁrst-line 
agents in both European and American 
guidelines.3,23 Pivmecillinam is registered in 
some Nordic European countries. It is orally 
bioavailable and has an extended spectrum 
against gram-negative Enterobacteriaceae. 
Its sole indication is urinary tract infection. 
Fosfomycin is registered in the USA as well 
as various European countries. Its favourable 
characteristics include the convenience of a 
single-dose regimen for acute uncomplicated 
cystitis, very good activity against a range 
of multi-drug resistant organisms including 
resistant Enterobacteriaceae and minimal 
propensity to induce resistance.23
Conclusion
Although antimicrobial resistance is 
an inevitable natural phenomenon, 
our professional behaviour is crucial in 
determining the rate and extent to which 
pathogens develop resistance. The emergence 
of ESBL-positive pathogens is challenging our 
practices and constraining the health care 
professional to rely increasingly on second-
line agents such as carbapenems.  
Clinical judgement in the choice of 
antibiotics, when indicated, is pivotal in 
ensuring therapeutic success while minimising 
the negative consequences of therapy. 
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worsen hypertension and heart failure. Patients on medication which predispose to 
hyperkalaemia should not use potassium containing preparations.
s  Cefuroxime is no longer recommended for the treatment of cystitis - Cephalosporins 
have been implicated as the driving force for resistance in Gram-negative pathogens.
s  Second generation quinolones should be avoided in the empirical treatment 
of cystitis as resistance is at a signiﬁcant level. The use quinolones promotes 
resistance not only among uropathogens but also other organisms.
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antimicrobial treatment. 
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